Loading…
Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration
Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to m...
Saved in:
Published in: | Journal of analytical toxicology 2004-04, Vol.28 (3), p.160-167 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | 167 |
container_issue | 3 |
container_start_page | 160 |
container_title | Journal of analytical toxicology |
container_volume | 28 |
creator | Gustafson, Richard A Kim, Insook Stout, Peter R Klette, Kevin L George, M P Moolchan, Eric T Levine, Barry Huestis, Marilyn A |
description | Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P /= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies. |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71865980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71865980</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23</originalsourceid><addsrcrecordid>eNp9kMtOAyEYhVlobK2-gmHljgQKzMDSNN6SJm7qevJzaYoyMAJN7CP41k6ibl2dxTnfWXxnaEmZ6IjoO7pAl7W-Uco61fELtGCS0Z4JuURfryUkKCc8HaCMYPN7SL4FW3HeY8ZIyoVoYqGY_HkizscGmjTfChxOrmQLKYEJKUcM--YLtjm1kmP0DucCEf9LuDGkUOemhZyu0PkeYvXXv7lCu4f73eaJbF8enzd3WzJJIYny0mjecQCzFpRpDs5JKah0yjApnDdcrznnTrqul0ppq83Mqd6BceDXfIVuf26nkj-OvrZhDNX6GCH5fKxDz1QntaLz8OZ3eDSjd8NUwjiLGv7c8W-7S22N</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71865980</pqid></control><display><type>article</type><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</creator><creatorcontrib>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</creatorcontrib><description>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration >/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</description><identifier>ISSN: 0146-4760</identifier><identifier>PMID: 15107145</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Analgesics, Non-Narcotic - administration & dosage ; Analgesics, Non-Narcotic - pharmacokinetics ; Cannabis ; Dosage Forms ; Dronabinol - administration & dosage ; Dronabinol - analogs & derivatives ; Dronabinol - pharmacokinetics ; Dronabinol - urine ; Gas Chromatography-Mass Spectrometry ; Half-Life ; Humans</subject><ispartof>Journal of analytical toxicology, 2004-04, Vol.28 (3), p.160-167</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15107145$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gustafson, Richard A</creatorcontrib><creatorcontrib>Kim, Insook</creatorcontrib><creatorcontrib>Stout, Peter R</creatorcontrib><creatorcontrib>Klette, Kevin L</creatorcontrib><creatorcontrib>George, M P</creatorcontrib><creatorcontrib>Moolchan, Eric T</creatorcontrib><creatorcontrib>Levine, Barry</creatorcontrib><creatorcontrib>Huestis, Marilyn A</creatorcontrib><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><title>Journal of analytical toxicology</title><addtitle>J Anal Toxicol</addtitle><description>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration >/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</description><subject>Administration, Oral</subject><subject>Analgesics, Non-Narcotic - administration & dosage</subject><subject>Analgesics, Non-Narcotic - pharmacokinetics</subject><subject>Cannabis</subject><subject>Dosage Forms</subject><subject>Dronabinol - administration & dosage</subject><subject>Dronabinol - analogs & derivatives</subject><subject>Dronabinol - pharmacokinetics</subject><subject>Dronabinol - urine</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>Half-Life</subject><subject>Humans</subject><issn>0146-4760</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOAyEYhVlobK2-gmHljgQKzMDSNN6SJm7qevJzaYoyMAJN7CP41k6ibl2dxTnfWXxnaEmZ6IjoO7pAl7W-Uco61fELtGCS0Z4JuURfryUkKCc8HaCMYPN7SL4FW3HeY8ZIyoVoYqGY_HkizscGmjTfChxOrmQLKYEJKUcM--YLtjm1kmP0DucCEf9LuDGkUOemhZyu0PkeYvXXv7lCu4f73eaJbF8enzd3WzJJIYny0mjecQCzFpRpDs5JKah0yjApnDdcrznnTrqul0ppq83Mqd6BceDXfIVuf26nkj-OvrZhDNX6GCH5fKxDz1QntaLz8OZ3eDSjd8NUwjiLGv7c8W-7S22N</recordid><startdate>200404</startdate><enddate>200404</enddate><creator>Gustafson, Richard A</creator><creator>Kim, Insook</creator><creator>Stout, Peter R</creator><creator>Klette, Kevin L</creator><creator>George, M P</creator><creator>Moolchan, Eric T</creator><creator>Levine, Barry</creator><creator>Huestis, Marilyn A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200404</creationdate><title>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</title><author>Gustafson, Richard A ; Kim, Insook ; Stout, Peter R ; Klette, Kevin L ; George, M P ; Moolchan, Eric T ; Levine, Barry ; Huestis, Marilyn A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Analgesics, Non-Narcotic - administration & dosage</topic><topic>Analgesics, Non-Narcotic - pharmacokinetics</topic><topic>Cannabis</topic><topic>Dosage Forms</topic><topic>Dronabinol - administration & dosage</topic><topic>Dronabinol - analogs & derivatives</topic><topic>Dronabinol - pharmacokinetics</topic><topic>Dronabinol - urine</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>Half-Life</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gustafson, Richard A</creatorcontrib><creatorcontrib>Kim, Insook</creatorcontrib><creatorcontrib>Stout, Peter R</creatorcontrib><creatorcontrib>Klette, Kevin L</creatorcontrib><creatorcontrib>George, M P</creatorcontrib><creatorcontrib>Moolchan, Eric T</creatorcontrib><creatorcontrib>Levine, Barry</creatorcontrib><creatorcontrib>Huestis, Marilyn A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of analytical toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gustafson, Richard A</au><au>Kim, Insook</au><au>Stout, Peter R</au><au>Klette, Kevin L</au><au>George, M P</au><au>Moolchan, Eric T</au><au>Levine, Barry</au><au>Huestis, Marilyn A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration</atitle><jtitle>Journal of analytical toxicology</jtitle><addtitle>J Anal Toxicol</addtitle><date>2004-04</date><risdate>2004</risdate><volume>28</volume><issue>3</issue><spage>160</spage><epage>167</epage><pages>160-167</pages><issn>0146-4760</issn><abstract>Understanding the pharmacokinetics of orally administered cannabinoids is vitally important for optimizing therapeutic usage and to determine the impact of positive tests on drug detection programs. In this study, gas chromatography-mass spectrometry (limit of quantitation = 2.5 ng/mL) was used to monitor the excretion of total 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol (THCCOOH) in 4381 urine voids collected from seven participants throughout a controlled clinical study of multiple oral doses of THC. The National Institute on Drug Abuse Institutional Review Board approved the study and each participant provided informed consent. Seven participants received 0, 0.39, 0.47, 7.5, and 14.8 mg THC/day for five days in this double blind, placebo-controlled, randomized protocol conducted on a closed research ward. No significant differences (P </= 0.05) were observed in mean time of maximum excretion rate, mean maximum excretion rate, and mean terminal elimination half-life (t(1/2)) between the four THC doses, with ranges of 67.4 to 94.9 h, 0.9 to 16.3 micro g/h, and 44.2 to 64.0 h, respectively. Mean apparent elimination t(1/2) of 24.1 +/- 7.8 and 21.1 +/- 4.3 h for the 7.5 and 14.8 mg/day doses, respectively, were calculated from the excretion rate curve prior to the last urine sample with a THCCOOH concentration >/= 15 ng/mL. An average of only 2.9 +/- 1.6%, 2.5 +/- 2.7%, 1.5 +/- 1.4%, and 0.6 +/- 0.5% of the THC in the 0.39, 0.47, 7.5, and 14.8 mg/day doses, respectively, was excreted as THCCOOH in the urine over each 14-day dosing session. This study demonstrated that the terminal urinary elimination t(1/2) of THCCOOH following oral administration was approximately two to three days for doses ranging from 0.39 to 14.8 mg/d. These data also demonstrate that the apparent urinary elimination t(1/2) of THCCOOH prior to reaching a 15 ng/mL concentration is significantly shorter than the terminal urinary elimination t(1/2). These controlled drug administration data should assist in the interpretation of urine cannabinoid results and provide clinicians with valuable information for future pharmacological studies.</abstract><cop>England</cop><pmid>15107145</pmid><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0146-4760 |
ispartof | Journal of analytical toxicology, 2004-04, Vol.28 (3), p.160-167 |
issn | 0146-4760 |
language | eng |
recordid | cdi_proquest_miscellaneous_71865980 |
source | Oxford Journals Online; Alma/SFX Local Collection |
subjects | Administration, Oral Analgesics, Non-Narcotic - administration & dosage Analgesics, Non-Narcotic - pharmacokinetics Cannabis Dosage Forms Dronabinol - administration & dosage Dronabinol - analogs & derivatives Dronabinol - pharmacokinetics Dronabinol - urine Gas Chromatography-Mass Spectrometry Half-Life Humans |
title | Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T14%3A05%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20pharmacokinetics%20of%2011-nor-9-carboxy-delta9-tetrahydrocannabinol%20after%20controlled%20oral%20delta9-tetrahydrocannabinol%20administration&rft.jtitle=Journal%20of%20analytical%20toxicology&rft.au=Gustafson,%20Richard%20A&rft.date=2004-04&rft.volume=28&rft.issue=3&rft.spage=160&rft.epage=167&rft.pages=160-167&rft.issn=0146-4760&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71865980%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p545-8e5b9363aab240193add55405d8b154deb392333d5d675889c9b54587dabdae23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71865980&rft_id=info:pmid/15107145&rfr_iscdi=true |